Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Indaptus Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities and Carry Forward Securities

	Security Type	Security Class Title	Fee Calculation or Carry Forward Rule			Amount Registered (1)			Proposed Maximum Offering Price Per Unit (2)			Maximum Aggregate Offering Price (3)		Fee Rate		Amount of Registration Fee
Fees to Be Paid	Equity	Common Stock, $0.01 par value per share (5)		457	(o)		-			-			0-		0.0001531-		0-
Fees to Be Paid	Equity	Preferred Stock, $0.01 par value per share (5)		457	(o)		-			-			0-		0.0001531-		0-
Fees to Be Paid	Other	Subscription Rights		457	(o)		-			-			0-		0.0001531-		0-
Fees to Be Paid	Other	Debt Securities		457	(o)		-			-			0-		0.0001531-		0-
Fees to Be Paid	Other	Warrants		457	(o)		-			-			0-		0.0001531-		0-
Fees to Be Paid	Other	Units		457	(o)		-			-			0-		0.0001531-		0-
Fees to Be Paid	Unallocated (Universal) Shelf	Unallocated (Universal) Shelf		457	(o)			(2)			(3)	$	200,000,000		0.0001531	$	30,620.00	(4)

	Total Offering Amounts												200,000,000			$	30,620.00
	Total Fees Previously Paid																—
	Total Fee Offsets															$	18,029.16
	Net Fee Due															$	12,590.84	(5)(6)

(1)	There is being registered hereunder an indeterminate number of shares of (a) common stock, (b) preferred stock, (c) subscription rights to purchase common stock, preferred stock or debt securities of the registrant (d) debt securities, (e) warrants to purchase common stock, preferred stock or debt securities of the registrant, and (f) units, consisting of some or all of these securities in any combination, as may be sold from time to time by the registrant. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. There is also being registered hereunder an indeterminate number of shares of common stock, preferred stock and debt securities as shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance. In no event will the aggregate offering price of all types of securities issued by the registrant pursuant to this registration statement exceed $200,000,000. Pursuant to Rule 416 under the Securities Act of 1933, as amended, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. If any debt securities are issued at an original issue discount, then the offering may be in such greater principal amount as shall result in a maximum aggregate offering price not to exceed $200,000,000 after the date hereof.

(2)	An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices.

(3)	Includes rights to acquire common stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.

(4)	Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or upon exercise of warrants registered hereunder. The aggregate maximum offering price of all securities issued by the registrant pursuant to this registration statement will not exceed $200,000,000.

(5)	The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act.

(6)	The Registrant previously filed a Registration Statement on Form S-3 with the Securities and Exchange Commission on September 1, 2022 (File No. 333-267236), which was declared effective on September 9, 2022 (the “Prior Registration Statement”), that registered an aggregate of $200,000,000 of an indeterminate number of securities to be offered by the Registrant from time to time. Of the $200,000,000 of securities registered on the Prior Registration Statement, for which the Registrant paid a filing fee of $18,540. In connection therewith, $194,489,409.30 of the securities remain unsold, leaving $18,029.16 in previously paid fees available for future offset (calculated at the fee rate in effect on the filing date of the Prior Registration Statement). In accordance with Rule 457(p) under the Securities Act, the Registrant is using $18,029.16 of the unused filing fees to offset the filing fee payable in connection with this filing. Accordingly, a registration fee of $12,590.84 is due to be paid at this time. Concurrently with the effectiveness of this registration statement, any offering of unsold securities pursuant to the Prior Registration Statement is hereby terminated.

Table 2: Fee Offset Claims and Sources

Registrant

or Filer

Name

Form

Filing

Type

File

Number

Initial

Filing

Date

Filing

Date

Fee Offset

Claimed

Security

Type

Associated

with Fee

Offset

Claimed

Security

Title

Associated

with Fee

Offset

Claimed

Unsold

Securities

Associated

with Fee

Offset

Claimed

Unsold

Aggregate

Offering

Amount

Associated

with Fee

Offset

Claimed

Fee Paid

with Fee

Offset

Source

Rule 457(p)

Fee Offset Claims

Indaptus Therapeutics, Inc.

S-3

333-265350

June 1, 2022

18,029.16

Unallocated (Universal) Shelf

(1)

Unallocated (Universal) Shelf

194,489,409.30

Fee Offset Sources

Indaptus Therapeutics, Inc.

S-3

333-265350

June 1, 2022

18,029.16

(1)

Pursuant to Rule 457(p) under the Securities Act, the Registrant is offsetting the registration fee due under this registration statement by $18,029.16, which represents the portion of the registration fee previously paid (after offset) with respect to $194,489,409.30 of unsold securities (the “Unsold Offset Securities”) previously registered on the Prior Registration Statement. The offering of the Unsold Offset Securities pursuant to the Prior Registration Statement associated with the claimed fee offset pursuant to Rule 457(p) have been completed or terminated.

N/A